Warning: The NCBI web site requires JavaScript to function. more...
p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2.
Vestey SB, Sen C, Calder CJ, Perks CM, Pignatelli M, Winters ZE.
Breast Cancer Res. 2004;6(5):R571-85. Epub 2004 Jul 29.
Related citations
Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome.
Eur J Cancer. 2005 May;41(7):1017-25.
Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome.
Vestey SB, Perks CM, Sen C, Calder CJ, Holly JM, Winters ZE.
Breast Cancer Res. 2005;7(1):R119-29. Epub 2004 Nov 23.
Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis.
Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, Harris AL.
Breast Cancer Res. 2003;5(6):R242-9. Epub 2003 Oct 3.
Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer.
Pinto AE, André S, Laranjeira C, Soares J.
Pathology. 2005 Feb;37(1):45-50.
Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR, Abd-Elwahed SR, Abdulwahed AR.
Cell Biol Int. 2008 Jun;32(6):698-707. Epub 2008 Jan 25.
Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
Rehman S, Crow J, Revell PA.
Pathol Oncol Res. 2000;6(4):256-63.
C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
Logullo AF, Lopes AB, Nonogaki S, Soares FA, Netto MM, Nishimoto IN, Brentani MM.
Oncol Rep. 2007 Jul;18(1):121-6.
Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implications.
Liu C, Zhang H, Shuang C, Lu Y, Jin F, Xu H, Lu P.
Med Oncol. 2010 Sep;27(3):747-52. Epub 2009 Aug 6.
Loss of bcl-2 expression in ductal carcinoma in situ of the breast relates to poor histological differentiation and to expression of p53 and c-erbB-2 proteins.
Quinn CM, Ostrowski JL, Harkins L, Rice AJ, Loney DP.
Histopathology. 1998 Dec;33(6):531-6.
Expression of cyclooxygenase-2 in breast carcinogenesis and its relation to HER-2/neu and p53 protein expression in invasive ductal carcinoma.
Cho MH, Yoon JH, Jaegal YJ, Choi YD, Lee JS, Lee JH, Nam JH, Choi C, Lee MC, Park CS, Woo Juhng S, Min KW.
Breast. 2006 Jun;15(3):390-8. Epub 2005 Sep 19.
Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
Park SS, Kim SW.
Oncol Rep. 2007 Jul;18(1):139-43.
Immunohistochemical expression of the beta-catenin-interacting protein B9L is associated with histological high nuclear grade and immunohistochemical ErbB2/HER-2 expression in breast cancers.
Toya H, Oyama T, Ohwada S, Togo N, Sakamoto I, Horiguchi J, Koibuchi Y, Adachi S, Jigami T, Nakajima T, Akiyama T.
Cancer Sci. 2007 Apr;98(4):484-90. Epub 2007 Feb 16.
CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S, Kapucuoglu N, Baspinar S, Inan G, Candir O.
Pathol Res Pract. 2006;202(8):569-76. Epub 2006 Jul 7.
Expression of vascular endothelial growth factor in invasive ductal carcinoma of the breast and the relation to angiogenesis and p53 and HER-2/neu protein expression.
Lee JS, Kim HS, Jung JJ, Kim YB, Lee MC, Park CS.
Appl Immunohistochem Mol Morphol. 2002 Dec;10(4):289-95.
p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein.
Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO.
Hum Pathol. 1993 May;24(5):463-8.
Genetic alterations of the p14ARF -hdm2-p53 regulatory pathway in breast carcinoma.
Ho GH, Calvano JE, Bisogna M, Abouezzi Z, Borgen PI, Cordón-Cardó C, van Zee KJ.
Breast Cancer Res Treat. 2001 Feb;65(3):225-32.
Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.
Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E.
J Natl Cancer Inst. 2001 Feb 21;93(4):309-14.
The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in 'pure' ductal carcinoma in situ of the breast.
de Roos MA, van der Vegt B, Peterse JL, Patriarca C, de Vries J, de Bock GH, Wesseling J.
Histopathology. 2007 Aug;51(2):227-38.
Increased cell size and Akt activation in HER-2/neu-overexpressing invasive ductal carcinoma of the breast.
Sastre-Garau X, Genin P, Rousseau A, Al Ghuzlan A, Nicolas A, Fréneaux P, Rosty C, Sigal-Zafrani B, Couturier J, Thiery JP, Magdelénat H, Vincent-Salomon A.
Histopathology. 2004 Aug;45(2):142-7.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on